Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.42
0.00 (0.00%)
Jun 4, 2026, 3:48 PM EDT - Market open
Ardelyx Revenue
Ardelyx had revenue of $94.47M in the quarter ending March 31, 2026, with 27.47% growth. This brings the company's revenue in the last twelve months to $427.68M, up 18.24% year-over-year. In the year 2025, Ardelyx had annual revenue of $407.32M with 22.09% growth.
Revenue (ttm)
$427.68M
Revenue Growth
+18.24%
P/S Ratio
3.13
Revenue / Employee
$874,599
Employees
489
Market Cap
1.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 407.32M | 73.71M | 22.09% |
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UroGen Pharma | 140.49M |
| KalVista Pharmaceuticals | 114.48M |
| Septerna | 72.26M |
| Immatics | 43.00M |
| Precigen | 31.60M |
| Maze Therapeutics | 20.00M |
| Inhibrx Biosciences | 1.30M |
ARDX News
- 1 day ago - Ardelyx Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Ardelyx Proxy statement: Proxy filing - Filings
- 16 days ago - Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 - GlobeNewsWire
- 16 days ago - Ardelyx Proxy statement: Proxy filing - Filings
- 4 weeks ago - Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings - GlobeNewsWire
- 4 weeks ago - Ardelyx reports Q1 EPS (15c), consensus (14c) - TheFly
- 4 weeks ago - Ardelyx Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Ardelyx Earnings release: Q1 2026 - Filings